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Abstract  
 Methamphetamine (METH) abuse is a serious public health issue, yet much regarding its 
neuroinflammatory role is unknown. This study investigates the mechanism underlying METH-
induced neuroinflammation. Two experiments were designed to investigate the role of microglia 
and high mobility group box 1 (HMGB1) protein in METH-induced neuroinflammation. Striatal 
microglia cell were isolated and cells were incubated with METH (10, 100, 1000, and 10,000 
ng/ml) or media alone for 24 h at 37° C, 5% CO2. In secondary experiments, microglia were 
exposed to higher concentrations to METH  (0.001, 0.01, 0.1, 1 and 10 mM). IL-1β mRNA and 
protein levels were measured using Real-Time PCR and an ELISA, respectively. The main effect 
of METH on IL-1β mRNA and protein levels was not significant. In experiment two, rats were 
injected with 1 of 3 doses of METH  (10, 5, 2.5, and 0 mg/kg, i.p.) to investigate the effect of 
different doses of METH on HMGB1 protein levels. HMGB1 protein was measured in ventral 
tegemental area (VTA), nucleus accumbens (NAC) and pre-frontal cortex (PFC) using an 
ELISA. The main effect of METH  on HMGB1 protein was significant at the 10 mg/kg dose and 
the main effect of METH on IL-1β protein was significant compared to the vehicle. Furthermore, 
there was a dose dependent decrease in HMGB1 after METH injection. Together, these findings 
suggest that HMGB1 plays a crucial role in mediating METH-induced neuroinflammation. Since 
it is known that HMGB1 binds to Toll-Like Receptors 2 and 4 in microglia cell surface, this 
paper proposes a potential mechanism for METH-induced neuroinflammation via HMGB1.  
 
 
 
Introduction 
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Abuse of the psychostimulant methamphetamine (METH ) has become an international 
health problem with an estimated 16 million people abusing the substance worldwide (United 
Nations Office on Drugs and Crime, 2007).  Additionally, the cost of METH use in United States 
was estimated to be $23.4 billion in 2005 (RAND Drug Policy Research Center, 2009). The 
increased number of people abusing METH, coupled with the rising burden of the drug on the 
economy, signifies the global effect METH can have in a population. However, it is important to 
keep in mind the effect of this drug on the individual. Beside the high rate of addiction after 
long-term METH abuse, METH also induces other debilitating effects including significant 
anxiety, confusion, mood disturbances, insomnia, psychotic symptoms, and violent behavior 
(National Institute on Drug Abuse, NIDA, 2013).  Addicts that attempt to abstain from further 
drug use suffer from both physiological and psychological effects such as depression, anxiety, 
fatigue, and the most obvious – intense craving for the drug (NIDA, 2013). Given the wide array 
of biological, psychological, and sociological factors underlying both METH addiction and 
withdrawal, it is easy to understand why treatments for METH abuse are limited. Therefore, it is 
crucial to continue research on METH and to use research methods that examine METH 
addiction in novel ways.   
One of the new ways to further understanding of METH addiction is to explore the 
mechanisms underlying the pro-inflammatory effects of the drug. Psychostimulants are able to 
activate specific components of the innate immune system following both chronic and acute 
exposure (Clark et al., 2012). Therefore, it is not surprising that METH is neuroinflammatory 
(Krasnova & Cadet, 2010), and indeed,  METH causes activation of microglia in the striatum, 
cortex and hippocampus two hours after an acute subcutaneous administration of 10 mg/kg dose 
(Escubedo et al., 1998). Importantly, these findings  suggest a role for microglia in inducing 
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neuroinflammation. Furthermore, METH can also cause an increase in the levels of interleukin -
1β (IL-1β), a pro-inflammatory cytokine (Numachi et al., 2007; Yamaguchi et al., 1991), 
primarily produced by the microglial cells in the brain. However, although there is ample 
evidence implicating METH as a neuroinflammatory substance, the mechanism(s) underlying 
METH-induced neuroinflammation is unknown.  
In sum, it is known that METH activates microglia in vivo, and that microglia are key in 
the neuroinflammatory process. Thus, an obvious strategy to investigate the mechanism 
underlying METH-induced neuroinflammation is to study the activation of microglia after direct 
METH exposure in vitro (experiment 1). The advantage of this strategy is that molecular 
mechanisms are far easier to study in vitro. 
Additionally, METH-induced neurotoxicity can lead to necrosis and neuroinflammation 
in dopaminergic brain regions. Rats treated acutely with various doses of METH show long-
lasting decreases in DA levels (Bittner et al., 1981; Cappon et al., 2000; Chapman et al., 2001; 
Eisch et al., 1992; Fukumura et al., 1998; Green et al., 1992; Kogan et al., 1976; Morgan and 
Gibb, 1980; Ricaurte et al., 1980; Richards et al., 1993; Truong et al., 2005; Wagner et al., 1979, 
1980; Walsh and Wagner, 1992), long-term reductions in the activity of tyrosine hydroxylase 
(TH) (Hotchkiss and Gibb, 1980; Hotchkiss et al., 1979; Morgan and Gibb, 1980), and marked 
decreases in the number of dopamine transporters (DAT) (Eisch et al., 1992; Guilarte et al., 
2003; Wagner et al., 1980) in the striatum. Additionally, there are many other ways in which 
METH can lead to dopamine terminal degeneration within the synapse (Figure 1; the details on 
METH neurotoxicity will be explained in detail below).  
It is known that the dying cells release various intracellular substances after undergoing 
necrosis. One of these substances is an alarmin/Danger Associated Molecular Pattern (DAMP) 
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called high mobility group box 1 protein (HMGB1). HMGB1 can activate microglia by ligating 
Toll Like Receptors (TLRs) expressed by microglia, thereby inducing inflammation. Since it is 
known that METH causes death of dopaminergic neurons, METH -induced neuroinflammation 
may be indirectly mediated by the neurotoxic effects of METH through release of alarmins such 
as HMGB1, which then induce a pro-inflammatory response in microglia. The role of HMGB1 
in METH -induced neuroinflammation has not been studied and is a focus of the present 
investigation. (experiment 2).  
 
Fig 1. Schematic rendering of cellular and molecular events involved in METH -induced DA terminal degeneration and neuronal 
apoptosis within the striatum. The figure summarizes findings of various studies that have addressed the role of DA, oxidative stress, and other 
mechanisms in METH  toxicity. METH  enters dopaminergic neurons via DAT and passive diffusion. Within these neurons, METH  enters 
synaptic vesicles through VMAT-2 and causes DA release into the cytoplasm via changes in pH balance. In the cytoplasm, DA auto-oxidizes to 
form toxic DA quinones with generation of superoxide radicals and hydrogen peroxides via quinone cycling. Subsequent formation of hydroxyl 
radicals through interactions of superoxides and hydrogen peroxide with transition metals leads to oxidative stress, mitochondrial dysfunctions 
and peroxidative damage to presynaptic membranes. The involvement of endogenous DA in METH  neurotoxicity is supported by findings that 
the TH inhibitor, METH yl-p-tyrosine, which blocks DA synthesis, affords protection against METH  toxicity. In addition, the role of DA is 
supported by observations that use of the MAO inhibitor, clorgyline, and of the irreversible inhibitor of vesicular transport, reserpine, which 
results in increases in cytoplasmic DA levels can exacerbate METH -induced toxicity. Together, these events are thought to be partly responsible 
for the loss of DA terminals. DA release from the terminals is also involved because the DAT inhibitor, amphonelic acid, which blocks METH -
induced DA release from DA terminals can also prevent damage to DA axons. The toxic effects of released DA might occur through activation of 
DA receptors because DA receptor antagonists block degeneration of DA terminals. Interactions of DA with D1 receptors on post-synaptic 
membrane cause activation of various transcription factors and subsequent upregulation of death cascades in postsynaptic neurons. These death 
cascades can be inhibited, in part, by the DA D1 antagonist, SCH23390. (Krasanova et al., 2009). 
Background  
Dopamine Mesolimbic pathway 
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METH, like many other addictive drugs, has a profound effect on the mesolimbic 
dopamine pathway (VTA, NAC, PFC). More specifically, METH primarily causes the release of 
monoamines, dopamine, serotonin, and norepinephrine (Paneka et al., 2012; Fig. 2).  It has been 
thought that METH not only blocks the norepinephrine, dopamine, and serotonin transporters in 
the brain like other psychostimulants, it also reverses these transporters to increase the levels of 
monoamines in the synapse (Koob & Moal, 2006). More specifically, METH modulates 
dopamine release by acting at two main molecular substrates on dopamine neuronal terminals: 
the vesicular monoamine transporter-2 (VMAT-2) and the plasmalemmal dopamine transporter 
(DAT) (Kahlig & Galli, 2003; Fig 2).  
 
DAT mediated METH effects 
Because DAT can transport dopamine bidirectionally, and the concentration of dopamine 
is much greater inside than outside the cell, the binding of METH on the extracellular side causes 
cytosolic dopamine to be reverse-transported outside the cell (Fleckenstein et al., 2007). 
Furthermore, DAT can also cause non-vesicular release of dopamine (Paneka et al., 2012). DAT 
can undergo a conformational change that enables brief bursts of dopamine efflux at a 
concentration resembling vesicular exocytotic release (Khalig et al., 2005). Lastly, DAT can also 
be internalized as a part of an endocytoic recycling pathway, thereby removing it from the 
plasmalemmal membrane, and ultimately hampering its capacity to decrease synaptic levels of 
dopamine (Paneka et al., 2012).  
 
VMAT-2 mediated METH effects  
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 VMAT-2 is an integral membrane protein that transports monoamines from the 
intracellular cytosol into synaptic vesicles (Brown et al., 2001; Fleckenstein et al., 2009; 
Weiland-Fiedler et al., 2004). METH causes synaptic vesicles to leak monoamines into the 
surrounding cytosol by disrupting a proton gradient set up by a hydrogen pump (Fleckenstein et 
al., 2007). Furthermore, METH, at physiological concentrations, also binds VAMT-2 and 
competitively inhibit vesicular monoamine uptake (Schwartz et al., 2006; Sulzer et al., 1993). 
This binding decreases sequestration of dopamine and thus leads to an increased cytosolic and 
synaptic monoamine concentration (Schwartz et al., 2006; Sulzer et al., 1993).  
Ultimately, these high levels of monoamines in the synapse, acute and long-term, due to 
action at DAT and VMAT-2, contribute to the many psychological and behavioral effects of 
METH. Furthermore, high doses of METH can not only lead to addiction, it can also cause 
neurotoxicity in dopaminergic cells (Krasnova et al., 2009).  
 
METH-induced neurotoxicity  
METH can cause long-term destruction of presynaptic dopaminergic and serotoninergic 
terminals (Krasnova & Cadet, 2010). METH enters the terminals/neurons via dopamine or 
serotonin transporters (DAT and SERT, respectively), and displaces both vesicular and 
intracellular DA/5-HT (Davidson et al., 2001). The displaced amines are oxidized by monoamine 
oxidase (MAO) to reactive oxygen species (ROS) (Cubells et al., 1990), with further production 
of ROS via hydrogen peroxide and nitric oxide (NO) (Bowyer et al., 1994). Additionally, METH 
causes depletions of 5-HT levels in rat striatum (Bakhit et al., 1981; Cappon et al., 2000; 
Friedman et al., 1998; Fukumura et al., 1998; Ricaurte et al., 1980; Richards et al., 1993; Walsh 
and Wagner, 1992), and also causes decreases in VMAT-2 binding (Guilarte et al., 2003). 
	   10	  
Furthermore, the neurotoxic damage to striatal axonal terminal is accompanied by astrocytosis 
(Bowyer et al., 1994; Cappon et al., 2000; Fukurama et al., 1998), and interestingly, microglial 
activation (Pubill et al., 2002). These processes ultimately leads to necrotic cell death (Davidson 
et al., 2001).  
 
Role of Dopamine in METH toxicity 
The role of dopamine in the mediation of METH toxicity is supported by studies showing 
that METH causes reactive oxygen species (ROS) production and oxidative stress in cultures 
containing dopamine neurons, but not in cultures devoid of dopamine neurons (Cubells et al., 
1990). Additionally, studies showing that METH-induced ROS in normal but not in dopamine 
depleted striatal synaptosomes further supports the involvement of dopamine in METH toxicity 
(Pubill et al., 2005). Furthermore, after its displacement into the cytoplasm by METH, dopamine 
rapidly auto-oxidizes to form super radicals, hydroxyl radicals, and hydrogen peroxides 
(Krasnova & Cadet, 2010). Ultimately, dopamine plays an integral role in METH induced 
neurotoxicity.  
 
Role of DAT and VMAT-2 in METH-induced toxicity  
 As mentioned above, METH interacts with both DAT and VMAT-2 to release 
monoamines into the extracellular space (Sulzer et al., 2005). Therefore, one can suppose that 
these proteins play a pivotal role in METH-induced toxicity. Indeed, several studies have shown 
that a DAT inhibitor was able to protect against METH-induced striatal dopamine depletion 
(Marek et al., 1990). Furthermore, DAT knockout mice are also protected against dopamine 
depletion, astrocytosis, and ROS production in the striatum (Fumagalli et al., 1998). 
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Additionally, pretreatment with reserpine, an irreversible inhibitor of vesicular transport, 
exacerbates toxicity of the psychostimulant, suggesting a role of VMAT-2 in METH-induced 
toxicity (Albers & Sonsalla, 1995).  
Ultimately, there are multiple mechanisms of METH-induced neurotoxicity, and almost 
all of these processes can lead to necrosis. As previously mentioned, when a cell undergoes 
necrosis, it doesn’t die a “quiet” death. Rather, it releases various intracellular substances to 
“warn” other cells of potential danger. This warning signal is primarily produced by immune 
cells, and in this case, the innate immune system of the brain.   
 
Innate Immunity in the Central Nervous System 
Microglia  
The innate immune system is he first line of defense against “danger” (Janeway, 2006), 
and microglia are the resident immune cell of the central nervous system (CNS). In a healthy 
CNS, the microglia are in a quiescent (surveillant) state, and when they encounter danger, they 
become activated and secrete various inflammatory mediators, such as pro-inflammatory 
cytokines (e.g. IL-1β), nitric oxide, chemokines, and reactive oxygen species (Colton, 2009). 
Microglia express many of the same receptors as do peripheral macrophages, including pattern 
recognition receptors (PRRs) that allow them to identify danger and foreign microorganisms. 
Among these PRRs, TLRs are the most extensively characterized (Barton and Kagan, 2009). 
TLRs are a family of highly conserved membrane or cytosolic proteins that transduce signals 
through a family of cytosolic Toll adapter proteins that link to downstream signaling cascades 
(Barton and Kagan, 2009). The activation of many of the TLR family members ultimately 
activates NF-kB as well as other transcription factors (Kawai and Akira, 2010; Salminen et al., 
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2008; Fig. 3). Of the PRRs, TLR2 and TLR4 have been the most intensively studied within the 
CNS and are densely expressed on microglia (Aravalli et al., 2007). Although TLRs bind many 
pathogenic substances, they also bind the alarmin HMGB1.  
 
High Mobility Group Box-1 Protein  
High Mobility Group Box-1 (HMGB1) is a nuclear protein that is ubiquitous in 
eukaryotic cells. In the nucleus, it functions to stabilize nucleosome formation and acts as a 
transcription factor-like protein that regulates the expression of several genes (West et al., 2004 
& Stros et al., 2004). It is to some degree also cytoplasmically expressed, as it shuttles back and 
forth from the nucleus (Stros 2010). More specifically , HMGB1 has recently been demonstrated 
to be involved in autophagy and in inflammasome activation in the intracellular compartment 
(Yang et al., 2012). Additionally, several recent studies have now found that HMGB1 is secreted 
by active macrophages, mature dendritic cells, and natural killer (NK) cells in response to injury, 
infection, or other inflammatory stimuli (Lotze & Tracey, 2005). Because of its extensive role in 
peripheral immunological function, HMGB1 is considered one of the main prototypes of danger 
associated molecular patterns (DAMPS) (Seong & Matzinger, 2004). DAMPs are naturally 
expressed in the cytosol or the nucleus, and currently include S100 proteins, heat-shock proteins 
(HSPs) and HMGB1. When released extracellularly, these proteins signal to the host that there is 
tissue damage (Lotze & Tracey, 2005). More specifically, extracellular HMGB1 is involved in a 
variety of immune responses, acting as a prototypic alarm signal (Yang et al.,2013). Given these 
distinct functions of HMGB1, one can assume that this protein has compartment-specific 
functions.  
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As a nuclear protein, HMGB1 is important for the regulation of transcription (Lotze & 
Tracey, 2005). It facilitates the binding of several regulatory protein complexes to DNA (Zeh & 
Lotze, 2005; Pasqualini, Sterner, Mercat & Allfrey, 1989; Prendergast, Onate, Christensen, 
Edwards, 1994; Zhang, Krieg, & Shapiro 1999), integrates transposons (Zayed, Izsvak, Khare, 
Heinemann & Lvics, 2003), enhances the interaction of other proteins with DNA, and enhances 
transcriptional activation (Knapp et al., 2004).  
 
Cytokine Activity of HMGB1 
HMGB1 is now recognized as a cytokine because it mediates systemic inflammatory 
responses, is secreted by activated immune cells, activates inflammatory response in immune and 
endothelial cells, and transduces cellular signals through receptor for advance glycation end-
products (RAGE), TLR2 and TLR4 (Lotze & Tracey, 2005; Fig. 4). HMGB1 can be released in 
two different ways: it can be secreted actively after DNA acetylation in the nucleus, or it can be 
released passively by cells undergoing necrosis (Lotze & Tracey, 2005; Fig 2). Since the focus of 
this project is necrosis induced HMGB1 release after METH exposure, only this aspect of 
HMGB1 release will be discussed. 
Necrotic cells, as opposed to apoptotic cells, can alert the immune system to danger 
because they lose membrane integrity and release their intracellular contents (Kono & Rock, 
2008).  As previously mentioned, one of these contents is the DAMP HMGB1. HMGB1 released 
passively by injured or necrotic cells, acts as a pro-inflammatory cytokine and functions as a 
major stimulus of necrosis-induced inflammation (Scaffidi, Misteli & Bianchi, 2002). When cells 
undergo necrosis, HMGB1 diffuses out into the extracellular space and drives inflammation 
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(Lotze & Tracey, 2005), by binding to TLR2 and TLR4 in human neutrophils and macrophages 
(Park et al., 2003).  
 
HMGB1 receptors and signaling  
TLR4 is the primary receptor involved in  macrophage activation, cytokine release, and 
tissue damage in response to HMGB1 (Yang et al., 2010). However, HMGB1 can also form 
heterocomplexes with other molecules, such as IL-1, CXCL12, DNA, RNA, or histones, which 
generate synergistic responses compared with those produced by individual components (Yang 
et al., 2013). Thus, both HMGB1 directly binding to TLRs or heterocomplexing with other 
molecules initiates innate immune response such as chemotactic activity and release of pro-
inflammatory cytokines. At this point, it is important to note that there are two distinct molecular 
structures of HMGB1 and that these structures determine its role in inflammation and immunity.  
 
Redox state and cytokine activity of HMGB1 
 Extracellular HMGB1 can act both as a chemoattractant for leukocytes and as a pro-
inflammatory mediator to release TNF, IL-1, IL-6 and other cytokines (Venereau et al., 2012). 
However, recent studies have shown the pro-inflammatory activity of HMGB1 depends on the 
redox state of three cysteine residues (Yang et al., 2012). More specifically, the oxidation of 
cysteines C23 and C45 results in a disulfide bond within the first HMG-box domain of HMGB1 
(also known as Box A) and the unpaired C106 must be in a thiol state for the protein to be pro-
inflammatory (Yang et al., 2012). Additionally, the all-thiol form of HMGB1 acts only as a 
chemotactic mediator. It is important to note that HMGB1 can switch between mutually 
exclusive redox states, where reduced cysteines make HMGB1 a chemoattractant, and a disulfide 
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bond makes it a pro-inflammatory cytokine (Venereau et al., 2012). Moreover, the pro-
inflammatory or partially oxidized form of HMGB1 binds to TLR4 and induces TNF release and 
NF-kB activation (Yang et al., 2012). Interestingly, the fully oxidized form of HMGB1 
(oxidation of C23, C45, and C106) exhibits neither chemotactic nor pro-inflammatory activity.  
In sum, HMGB1 is a complex protein whose activity is not only compartment specific 
(nuclear vs. cytosolic vs. extracellular), it is also dependent on the redox state of the protein. 
 
Summary and Key Research Objectives  
 Given the effects of METH on the innate immune system within the CNS, the role of 
microglia in METH-induced neuroinflammation is pivotal. As previously mentioned, microglia 
express various PRRs on their surfaces to bind pathogen, foreign substances, and alarmins. 
Furthermore, METH in high doses has neurotoxic effects causing dopamine cell necrosis, 
followed by the release of alarmins. Given these two points, one can now try to elucidate the 
mechanism underlying METH-induced neuroinflammation.  The inflammation can be caused by 
the direct binding of METH to various PRRs in microglia, or due to the release of HMGB1 from 
necrotic cells, and subsequent binding of HMGB1 to TLRs on microglia. Given these two 
potential mechanisms by which METH  can induce neuroinflammation, this project had two key 
objectives: 
1. Determine whether the neuroinflammatory response to METH  is due to the induction of 
pro-inflammatory cytokines through direct activation of striatal microglia, or 
2. Determine whether the neuroinflammatory response in the VTA, PFC, and NAC, is due 
to the release of alarmins after cell apoptosis and necrosis after METH  induced 
neurotoxicity.  
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Methods 
Animals 
Male Sprague-Dawley rats, weighing approximately 275 grams (60-90 days old; Harlan 
Sprague-Dawley, Inc., Indianapolis, IN, USA) were pair-housed with food and water available 
ad libitum. The colony was maintained at 25 °C on a 12-h light/dark cycle (lights on at 07:00 h). 
All experimental procedures were conducted in accord with the University of Colorado 
Institutional Animal Care and Use Committee. 
 
Reagents 
METH  was obtained from Sigma (St.Louis, MO). 
 
In vitro effect of METH  on microglia (Experiment 1) 
Tissue collection  
Animals were given a lethal dose of sodium pentobarbitaland then transcardially perfused 
with ice-cold saline (0.9%) for 3 min to remove peripheral immune leukocytes from the CNS 
vasculature. Brains were rapidly extracted and placed on ice, striatum dissected, and microglia 
were immediately isolated.  
 
Ex vivo immune stimulation of striatal microglia with METH  
Striatal microglia were isolated using a Percoll density gradient as previously described 
(Frank et al., 2006). It has been previously shown (Frank et al., 2006) that this microglia 
isolation procedure yields highly pure microglia (Iba-1+/MHCII+/CD163-/GFAP-). Microglia 
were suspended in DMEM+10% FBS and microglia concentration determined by trypan blue 
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exclusion. Microglia concentration was adjusted to a density of 5 x 10^3/100 µl and added to 
individual wells of a 96-well v-bottom plate. METH was utilized to challenge microglia ex vivo. 
METH   was dissolved in tissue culture media (DMEM+10% FBS). In initial experiments, cells 
were incubated with METH   (10, 100, 1000, and 10,000 ng/ml) or media alone for 24 h at 37° 
C, 5% CO2. In secondary experiments, microglia were exposed to higher concentrations to 
METH  (0.001, 0.01, 0.1, 1 and 10 mM). The plate was centrifuged at 1000 x g for 10 min at 4 
°C to pellet cells. Supernatant was removed for ELISA analysis of IL-1β protein. Cells were 
washed 1x in ice cold PBS and centrifuged at 1000 x g for 10 min at 4 °C. Cell 
lysis/homogenization and cDNA synthesis was performed according to the manufacturer’s 
protocol using the SuperScript III CellsDirect cDNA Synthesis System (Invitrogen, Carlsbad, 
CA). 
 
Real time (RT-PCR) measurement of gene expression 
A detailed description of the PCR amplification protocol has been published previously 
(Frank et al., 2006). cDNA sequences were obtained from Genbank at the National Center for 
Biotechnology Information (NCBI; www.ncbi.nlm.nih.gov). Primer sequences were designed 
using the Operon Oligo Analysis Tool  (http://www.operon.com/technical/toolkit.aspx) and 
tested for sequence specificity using the Basic Local Alignment Search Tool at NCBI. Primers 
were obtained from Invitrogen. Primer specificity was verified by melt curve analyses. All 
primers were designed to span exon/exon boundaries and thus exclude amplification of genomic 
DNA. IL-1β (F- CCTTGTGCAAGTGTCTGAAG, R- GGGCTTGGAAGCAATCCTTA), β-
Actin (F- TTCCTTCCTGGGTATGGAAT, R- GAGGAGCAATGATCTTGATC) 
PCR amplification of cDNA was performed using the Quantitect SYBR Green PCR Kit (Qiagen, 
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Valencia, CA). Formation of PCR product was monitored in real time using the MyiQ Single-
Color Real-Time PCR Detection System (BioRad, Hercules, CA). Relative gene expression was 
determined by taking the expression ratio of the gene of interest to β-Actin. 
 
IL-1β ELISA 
IL-1β protein was measured using a commercially available ELISA kit (R & D Systems, 
Minneapolis, MN). IL-1β protein was assayed according to the manufacturers’ protocol. 
 
In vivo effect of METH  on HMGB1 and IL-1 beta  (Experiment 2) 
Intraperitoneal Injection of METH  
 Rats were injected with 1 of 3 doses of METH  (10, 5, 2.5, and 0 mg/kg, i.p.) to 
investigate the effect of different doses of METH  on HMGB1 protein levels in the brain. Two 
hours later, the rats were perfused with saline and whole brains were dissected.  Brains were 
immediately placed into chilled isopentane to flash freeze the tissue. The tissues were stored at -
80o C.  
 
Tissue Processing 
Tissue micropunches from ventral tegmental area (VTA), nucleus accumbens (NAc), and 
prefrontal cortex (PFC) were sonicated in 100 ul of tissue extraction buffer (Invitrogen, 
Camarillo, CA) containing a protease inhibitor cocktail (Sigma, St. Louis, IL). Sonicated 
samples were centrifuged at 14,000 rpm, 4o C for 10 min. Supernatants were collected and stored 
at -80o C.  
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Total Protein Quantification  
The protein concentrations from each sample were determined using a Bradford protein 
assay. 
 
HMGB1 ELISA 
HMGB1 protein was measured using a commercially available ELISA kit (Chondrex,). 
HMGB1 protein was assayed according to the manufacturers’ protocol. 
 
Statistical analysis and data presentation 
All data are presented as mean ± SEM. For experiment 1, statistical analysis consisted of 
a one-way ANOVA followed by post-hoc tests (Tukey's). For experiment 2, a mixed design 
ANOVA was conducted with brain region as the within subjects factor and METH  dose as the 
between subjects factor followed by post-hoc tests (Tukey's). Statistical analysis was performed 
using Prism 5 (Graphpad Software, Inc., La Jolla, CA). Threshold for statistical significance was 
set at α = 0.05. All data were normalized (log scaled) before doing statistical analysis.  
 
Results 
Experiment 1: Effect of METH on the microglia pro-inflammatory response in vitro 
The main effect of METH  on IL-1β protein expression was not significant  (Fig. 4) (F = 
0.40; p = 0.81), and the main effect of METH  on IL-1β mRNA expression was not significant (F 
= 1.1; p = 0.40).   
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Experiment 1B: Effect of higher METH concentration on the microglia pro-inflammatory 
response in vitro 
 The main effect of METH on IL-1β protein expression, even at the higher doses of 
METH, did not show a dose dependent increase. (Fig. 4).  
 
Experiment 2: Effect of METH  on HMGB1 and IL-1β in brain   
HHMGB1 
The main effect of METH  on HMGB1 protein was significant at the 10 mg/kg dose, 
regardless of the brain region (F = 4.54; p = 0.0154), when compared to the vehicle (Fig. 5). 
METH significantly decreased HMGB1 levels. The main effect of METH on HMGB1 protein 
was not significant at any other dose. There was a dose dependent decrease of HMGB1 levels. 
The interaction between brain region and METH  dose was significant (F = 2.374, p = 0.049).  
IL-1β.  
 The main effect of METH on IL-1β protein was significant (F=5.898, p=.0057), when 
compared to vehicle (Fig. 5). METH significantly increased IL-1β levels. The interaction 
between brain region and IL-1β protein level was significant (F=2.374, p=.0482).  
 
Post-hoc comparison within brain region    
Post-hoc analyses were then conducted separately for each brain region. For NAC, 10 
mg/kg METH  significantly increased IL-1b compared to vehicle control (p <  0.01) and the 2.5 
mg/kg METH  dose (p < 0.01). For PFC, 2.5 mg/kg METH  significantly increased IL-1b 
compared to vehicle control (p <  0.05). For VTA, 10 mg/kg METH  significantly increased IL-
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1b compared to vehicle control (p <  0.05). The main effect of METH  on Il-1β was significant 
(F=2.374; p=.0492), when compared to the vehicle.  
 
Discussion 
The aim of this project was to study the mechanism underlying METH-induced 
neuroinflammation. Since microglia was not activated after METH introduction, the present 
study has shown that METH-induced neuroinflammation is not directly mediated by microglia.   
However, because there was a dose dependent decrease in HMGB1 after METH injection, 
neuroinflammation could be indirectly mediated by HGMB1. Since there was a dose dependent 
decrease in HMGB1 after METH injection, the role of HMGB1 must be investigated further. 
However, there are some key caveats that we must keep in mind when talking about the role of 
HMGB1 in METH-induced neuroinflammation.  
Limitations of the experiment 
First, given the nature of the study, total HMGB1 was measured, instead of 
differentiating between the nuclear, cytoplasmic, and extracellular compartments. Ideally, in 
order to measure the amount of HMGB1 released, extracellular HMGB1 pre and post METH 
injection should have been measured. However, given the large size of HMGB1, using 
microdialysis was not possible.  
Furthermore, as previously mentioned, only the oxidized form of HMGB1 has the 
capacity to act as a cytokine to mediate pro-inflammatory responses. Therefore, using mass 
spectrometry to differentiate between the oxidized and chemotactic HMGB1 would have better 
delineated the role of HMGB1 in METH-induced neuroinflammation.  
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Additionally, instead of observing an increase in HMGB1 levels as hypothesized, a dose 
dependent decrease was measured. One of the reasons for a decrease in HMGB1 could be 
because of the protein heterocomplexing with other molecules after its release. In this case, the 
HMGB1 could not have been detected by the ELISA assay.  
Furthermore, the dose dependent decrease in total HMGB1 levels could also be attributed 
to the fact that the protein was rapidly degraded once it was released into the extracellular space. 
Previous studies have demonstrated the time-dependent decrease of HMGB1 after the onset of 
brain ischemia (Qui et al., 2008). The authors posited that HMGB1 was rapidly released from the 
cytosol after brain ischemia and was then degraded. Therefore, the decrease in HMGB1 
following METH exposure can be interpreted as an increase in extracellular HMGB1 levels.  
Despite the limitations in the experiment, there is a clear relationship between HMGB1 
and neuroinflammation following acute METH injection. Having said that, we posit a potential 
mechanism underlying METH-induced neuroinflammation, mediated by HMGB1. A) As the 
cells undergo necrosis, they passively release HMGB1 into the extracellular space. B) HMGB1 
then binds to the TLR2 and TLR4 on microglia cells. C) This binding activates microglia cells to 
induce NF-kB transcription, subsequently producing IL-1β. However, further studies must be 
done to fully understand the role HMGB1 plays in METH-induced neuroinflammation. 
Future studies 
 This experiment measured HMGB1 protein levels, but measuring HMGB1 mRNA levels 
would provide key insights into the role that HMGB1 plays in neuroinflammation. Additionally, 
in order to establish whether HMGB1 is necessary to mediate METH-induced 
neuroinflammation, an antagonist must be used to block its activity in the brain. Anti-HMGB1 
antibodies have been used in other studies to investigate the role of HMGB1 in sepsis (Yang et 
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al., 2003), therefore, blocking HMGB1 using anti-HMGB1 antibodies via microinjection in the 
brain would be a crucial next step to better understand the role of HMGB1 in METH-induced 
neuroinflammation.  
 Ultimately, this study provided the first step in studying the role of HMGB1 in METH-
induced neuroinflammation. Because METH addiction and toxicity are increasingly becoming a 
bigger public health issue, studying this drug of abuse through a inflammatory point of view 
could provide key insights in METH addiction, and subsequently clinical usage.  
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Figure Legends 
 
Figure 1. Schematic rendering of cellular and molecular events involved in meth-induced DA 
terminal degeneration and neuronal apoptosis within the striatum. The figure summarizes 
findings of various studies that have addressed the role of DA, oxidative stress, and other 
mechanisms in METH toxicity. METH enters dopaminergic neurons via DAT and passive 
diffusion. Within these neurons, METH enters synaptic vesicles through VMAT-2 and causes 
DA release into the cytoplasm via changes in pH balance. In the cytoplasm, DA auto-oxidizes to 
form toxic DA quinones with generation of superoxide radicals and hydrogen peroxides via 
quinone cycling. Subsequent formation of hydroxyl radicals through interactions of superoxides 
and hydrogen peroxide with transition metals leads to oxidative stress, mitochondrial 
dysfunctions and peroxidative damage to presynaptic membranes. The involvement of 
endogenous DA in METH neurotoxicity is supported by findings that the TH inhibitor, methyl-p-
tyrosine, which blocks DA synthesis, affords protection against METH toxicity. In addition, the 
role of DA is supported by observations that use of the MAO inhibitor, clorgyline, and of the 
irreversible inhibitor of vesicular transport, reserpine, which results in increases in cytoplasmic 
DA levels can exacerbate METH-induced toxicity. Together, these events are thought to be 
partly responsible for the loss of DA terminals. DA release from the terminals is also involved 
because the DAT inhibitor, amphonelic acid, which blocks METH-induced DA release from DA 
terminals, can also prevent damage to DA axons. The toxic effects of released DA might occur 
through activation of DA receptors because DA receptor antagonists block degeneration of DA 
terminals. Interactions of DA with D1 receptors on post-synaptic membrane cause activation of 
various transcription factors and subsequent upregulation of death cascades in postsynaptic 
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neurons. These death cascades can be inhibited, in part, by the DA D1 antagonist; SCH23390. 
(Krasnova et al., 2009).  
 
Figure 2. Physiological mechanisms by which methamphetamine increases synaptic levels of 
monoamines, principally dopamine. Mechanisms include the redistribution of monoamines from 
synaptic vesicles to the cytosol (1), and the reverse transport of neurotransmitter through plasma 
membrane transporters. In addition, amphetamines have been shown to block the activity of 
dopamine transporters (DATs) (2), similar to cocaine, and decrease expression of dopamine 
transporters at the cell surface (3). Amphetamines can increase cytosolic levels of monoamines 
by inhibiting the activity of monoamine oxidase (MAO) (4), and increase activity and expression 
of tyrosine hydroxylase (5) (Paneka et al., 2013).  
 
Figure 3. TLR4 signal transduction requires recruitment of myeloid differentiation factor 2 
(MD-2) and soluble CD14 that flows in the bloodstream. The resulting complex confers an 
intracellular signal via the Toll/IL-1 receptor (TIR) domain that either follows a MyD88-
dependent or MyD88-independent pathway. In the MyD88-dependent pathway, the resulting 
signal is then transduced to IL-1 receptor- associated kinases (IRAKs) that facilitate subsequent 
phosphorylations. These phosphorylations ultimately cause IκB-α, a cytoplasmic protein that 
binds the nuclear localization sequence of the p65 subunit of NF-κB, to dissociate from NF-κB. 
Binding of TLR4 also activates the PI3K/Akt/NF-κB pathway. NF-κB then translocates to the 
nucleus to promote transcription of pro-inflammatory cytokines such as IL-1β and IL-6. TLR2 
activity requires CD14 and contributes to NF-κB activation. (Gangloff et al., 2003; Shimazu et 
al., 1999; Zhang, 2011).  
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Figure 4. Cellular events associated with disease, injury, or toxicant-induced gliosis. Neural 
elements of the CNS (neurons or glia) serve as targets for neurotoxic insults. The damaged cells 
serve as a source of signals that activate microglia or astroglia, cellular responses collectively 
referred to as gliosis. Gliosis is characterized by the expression of a variety of glial genes and 
proteins. The possibility exists that neurotoxic exposures directly activate microglia and astroglia 
(large downward arrow), with the en- suing elaboration of glia-derived neuroinflammatory 
mediators (large upward arrow) causing damage to neural targets. bFGF: basic fibroblast growth 
factor; FcR: Fc receptor; GDNF: glia-derived neurotrophic factor; GFAP: glial fibrillary acidic 
protein; GLUT: glucose transporter; HSP: heat-shock protein; ICAM: intercellular cell-adhesion 
molecule; iNOS: inducible nitric oxide synthase: MCP-1: monocyte chemoattractant protein 
(CCL2 in new nomenclature); MHC: major histocompatibility complex; MRF: microglial 
response factor; NGF: nerve growth factor; TNF: tumor necrosis factor. (O’Callaghan, Sriram, & 
Miller, 2008).  
 
 Figure 5. Striatal microglial cells were exposed to 0, 10, 100, 1000, 10000 ng/ml of METH for 
24 hours. Il-1β mRNA expression (Figure 3A) and protein expression (Figure 3B) were 
measured using ELISA as a percentage of media control. An MTT Assay was performed to test 
cell viability, and METH failed to significantly alter cell viability (Figure 3D).   
 
Figure 6. Twenty-four animals were given four doses of METH (0, 2.5, 5, 10 mg/kg) via acute 
injection. Brains were dissected two hours later and HMGB1 and IL-1β proteins levels measured 
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in NAc, PFC, and VTA. The main effect of Meth on HMGB1 protein was significant at 10 
mg/kg dose regardless of the brain region (F=5.11; p=.0088), when compared to the vehicle  
 (Figure 4A). There was no main effect of Meth on HMGB1 when looking at brain regions 
independently (p=.1715), when compared to the vehicle. The main effect of meth on Il-1β was 
significant (F=2.374; p=.0492), when compared to the vehicle (Figure 4B).  
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A.     mRNA expression  
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C.      Il-1β  Protein expression 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D.      Cell viability   
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A.      HMGB1 Protein expression  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.      Il-1β  Protein expression 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 
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